NK4 gene therapy can inhibit growth, invasion, metastasis and angiogenesis in a variety of tumors, including breast cancer, prostate cancer, colon cancer, mesothelioma, lung cancer, pancreatic cancer and brain cancer (6). Here, IL32 is linked to prostate cancer.